Patients with ANCA-associated vasculitis (AAV) and end-stage kidney disease (ESKD) are at higher risk for death following kidney transplantation compared with patients who do not have AAV ...

Östlund Y, Saeed A, Mihovilovic K. Patient outcomes in a Swedish single-centre cohort of ANCA-associated vasculitis with renal involvement. Presented at: ERA 2023, June 15-18, Milan, Italy.

GALLEN, Switzerland — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., ...

Nervous system involvement was common among a cohort of patients with AAV, with these individuals showing less severe renal impairment.

TOPLINE: A data-driven subclassification of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis has identified five distinct clusters with varying degrees of kidney involvement and ...

Emerging ANCA Vasculitis therapies in the different phases of clinical trials are- MT-2990, KYV-101, Povetacicept, NM8074, Sparsentan, Abatacept, BDB-001 injection, Avacopan, Iptacopan, ALE.F02 ...

But in ANCA vasculitis, complements are normal, and the kidney biopsy does not have any staining, and we call it Pauci immune disease because we do not see complement deposition.

Patients with ANCA-associated vasculitis receiving low glucocorticoid doses as per the PEXIVAS trial faced an increased risk for death, renal failure, progression, or relapse in this real-world study.

In 2022, the market size of ANCA Associated Vasculitis was highest in the US among the 7MM, accounting for approximately USD 620 million, which is expected to increase by 2032.

ANCA-associated vasculitis — a rare and life-threatening autoimmune disease — affects various organs such as lungs and kidneys simultaneously.

Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitisSAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI ...